The Clinical Impact of the Pulmonary Embolism Severity Index on the Length of Hospital Stay of Patients with Pulmonary Embolism: A Randomized Controlled Trial.

Pulmonary Embolism Severity Index length of hospital stay pulmonary embolism

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
07 Apr 2024
Historique:
received: 28 02 2024
revised: 02 04 2024
accepted: 04 04 2024
medline: 13 4 2024
pubmed: 13 4 2024
entrez: 13 4 2024
Statut: epublish

Résumé

The Pulmonary Embolism Severity Index (PESI) is an extensively validated prognostic score, but impact analyses of the PESI on management strategies, outcomes and health care costs are lacking. Our aim was to assess whether the adoption of the PESI for patients admitted to an internal medicine ward has the potential to safely reduce the length of hospital stay (LOS). We carried out a multicenter randomized controlled trial, enrolling consecutive adult outpatients diagnosed with acute PE and admitted to an internal medicine ward. Within 48 h after diagnosis, the treating physicians were randomized, for every patient, to calculate and report the PESI in the clinical record form on top of the standard of care (experimental arm) or to continue routine clinical practice (standard of care). The ClinicalTrials.gov identifier is NCT03002467. This study was prematurely stopped due to slow recruitment. A total of 118 patients were enrolled at six internal medicine units from 2016 to 2019. The treating physicians were randomized to the use of the PESI for 59 patients or to the standard of care for 59 patients. No difference in the median LOS was found between the experimental arm (8, IQR 6-12) and the standard-of-care arm (8, IQR 6-12) ( The formal calculation of the PESI in the patients already admitted to internal medicine units did not impact the length of hospital stay.

Sections du résumé

BACKGROUND BACKGROUND
The Pulmonary Embolism Severity Index (PESI) is an extensively validated prognostic score, but impact analyses of the PESI on management strategies, outcomes and health care costs are lacking. Our aim was to assess whether the adoption of the PESI for patients admitted to an internal medicine ward has the potential to safely reduce the length of hospital stay (LOS).
METHODS METHODS
We carried out a multicenter randomized controlled trial, enrolling consecutive adult outpatients diagnosed with acute PE and admitted to an internal medicine ward. Within 48 h after diagnosis, the treating physicians were randomized, for every patient, to calculate and report the PESI in the clinical record form on top of the standard of care (experimental arm) or to continue routine clinical practice (standard of care). The ClinicalTrials.gov identifier is NCT03002467.
RESULTS RESULTS
This study was prematurely stopped due to slow recruitment. A total of 118 patients were enrolled at six internal medicine units from 2016 to 2019. The treating physicians were randomized to the use of the PESI for 59 patients or to the standard of care for 59 patients. No difference in the median LOS was found between the experimental arm (8, IQR 6-12) and the standard-of-care arm (8, IQR 6-12) (
CONCLUSIONS CONCLUSIONS
The formal calculation of the PESI in the patients already admitted to internal medicine units did not impact the length of hospital stay.

Identifiants

pubmed: 38611689
pii: diagnostics14070776
doi: 10.3390/diagnostics14070776
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT03002467']

Types de publication

Journal Article

Langues

eng

Auteurs

Marco Paolo Donadini (MP)

Thrombosis and Haemostasis Center, Ospedale di Circolo, ASST Sette Laghi, 21100 Varese, Italy.
Research Center on Thromboembolic Diseases and Antithrombotic Therapies, University of Insubria, 21100 Varese and 22100 Como, Italy.

Nicola Mumoli (N)

Department of Internal Medicine, Magenta Hospital, 20013 Magenta, Italy.
Presidio Ospedaliero di Livorno, Azienda USL Toscana Nord Ovest, 57124 Livorno, Italy.

Patrizia Fenu (P)

Presidio Ospedaliero di Cecina, Azienda USL Toscana Nord Ovest, 57023 Cecina, Italy.

Fulvio Pomero (F)

Internal Medicine Unit, Michele e Pietro Ferrero Hospital, 12060 Verduno, Italy.

Roberta Re (R)

Medicina Interna, Ospedale S. Andrea, ASL Vercelli, 13100 Vercelli, Italy.

Gerardo Palmiero (G)

Ospedale Versilia, Azienda USL Toscana Nord Ovest, 55049 Viareggio, Italy.

Laura Spadafora (L)

Internal Medicine Unit, Michele e Pietro Ferrero Hospital, 12060 Verduno, Italy.

Valeria Mazzi (V)

Presidio Ospedaliero di Livorno, Azienda USL Toscana Nord Ovest, 57124 Livorno, Italy.

Alessandra Grittini (A)

Department of Internal Medicine, Magenta Hospital, 20013 Magenta, Italy.

Lorenza Bertù (L)

Research Center on Thromboembolic Diseases and Antithrombotic Therapies, University of Insubria, 21100 Varese and 22100 Como, Italy.

Drahomir Aujesky (D)

Department of General Internal Medicine, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.

Francesco Dentali (F)

Thrombosis and Haemostasis Center, Ospedale di Circolo, ASST Sette Laghi, 21100 Varese, Italy.
Research Center on Thromboembolic Diseases and Antithrombotic Therapies, University of Insubria, 21100 Varese and 22100 Como, Italy.

Walter Ageno (W)

Thrombosis and Haemostasis Center, Ospedale di Circolo, ASST Sette Laghi, 21100 Varese, Italy.
Research Center on Thromboembolic Diseases and Antithrombotic Therapies, University of Insubria, 21100 Varese and 22100 Como, Italy.

Alessandro Squizzato (A)

Research Center on Thromboembolic Diseases and Antithrombotic Therapies, University of Insubria, 21100 Varese and 22100 Como, Italy.
Internal Medicine Unit, 'Sant'Anna' Hospital, ASST Lariana, 22042 San Fermo della Battagli, Italy.

Classifications MeSH